NEUROBLASTOMA

This study tests an oral drug called DFMO in children and young adults with high-risk neuroblastoma who are currently in remission. The goal is to see if taking DFMO for two years can prevent the cancer from returning. About 441 participants will take the drug twice daily and be …

This study is for children newly diagnosed with high-risk neuroblastoma, a serious nerve cell cancer. Researchers are adding a drug called naxitamab to the usual chemotherapy to see if it helps more tumors shrink or disappear. About 93 children will take part, and the goal is to …

This expanded access program provides a radioactive drug called 131 I-MIBG to children (age 1 and older) with neuroblastoma that has not responded to standard treatments or has come back. The drug targets and kills cancer cells with radiation. Early results from a related study s…

This study is testing a precise type of radiation called proton beam therapy for children with neuroblastoma, a nerve cell cancer. The goal is to see if it can reduce side effects like heart, lung, and growth problems compared to standard radiation. About 30 participants will rec…

This study tests a radioactive drug called I-MIBG in people with neuroblastoma or related tumors that have not responded to standard treatments. The drug delivers radiation directly to cancer cells to shrink tumors. Researchers want to see how well it works and how safe it is for…

This program provides the drug DFMO to children and young adults (up to age 30) with rare, relapsed tumors like neuroblastoma or medulloblastoma that have certain genetic markers. The goal is to control the disease by targeting these markers. Participants must have tried other tr…

This study is for children newly diagnosed with high-risk neuroblastoma, a serious nerve tissue cancer. It first uses genetic tests to pick the best chemotherapy drugs for each child. Then, it compares standard immunotherapy alone versus immunotherapy plus an extra drug called DF…

This study tests an experimental oral drug called AMXT 1501 combined with another drug, eflornithine (DFMO), in children and young adults up to age 21 with certain cancers like neuroblastoma, brain tumors, and sarcomas. The goal is to find the best dose and see if the combination…

This study tests whether adding extra chemotherapy (intrathecal topotecan and maintenance pills) after standard high-dose chemo is safe and doable for children under 6 with high-risk embryonal brain tumors. About 15 children will receive the additional treatment to see if it can …

This study tests a bivalent vaccine (with an immune booster called OPT-821) plus oral β-glucan in 94 people with high-risk neuroblastoma that is in complete remission. The goal is to see which schedule of β-glucan helps the body make more antibodies against the cancer, potentiall…

This early-phase study tests a new treatment for children whose neuroblastoma or osteosarcoma has returned or not responded to standard therapy. The treatment uses the patient's own immune T-cells, modified in a lab to better recognize and attack cancer cells that carry a marker …

This early-phase study tests a stem cell transplant from a half-matched donor for children with blood cancers or solid tumors that have come back or are hard to treat. The transplant uses a special method to remove certain immune cells, and patients also receive a drug called zol…

This study tests a two-step treatment for children and young adults with high-risk neuroblastoma. After initial chemotherapy, patients receive two rounds of very strong chemotherapy, each followed by a transplant of their own stem cells. The goal is to improve the time without th…

This early-phase study tests a new drug called rhIL-15 alongside three standard chemotherapy drugs for children and young adults (ages 3 to 35) with neuroblastoma that has returned or not responded to prior treatment. The goal is to find a safe dose and see if the combination can…

This study tests whether adding a radioactive drug (131I-MIBG) or a targeted pill (lorlatinib) to standard therapy helps children with high-risk neuroblastoma live longer without the cancer coming back. About 750 children and young adults (ages 1 to 30) with newly diagnosed high-…

This early-stage study tests a treatment where a child's own immune cells are collected, modified to better recognize and attack certain solid tumors, and then given back as a one-time infusion. The main goal is to find the safest dose and see if it can shrink tumors. The study i…

This study tests whether adding the drug dinutuximab to standard chemotherapy and other treatments helps children with high-risk neuroblastoma live longer without the cancer coming back. About 478 children and young adults up to age 30 with newly diagnosed high-risk neuroblastoma…

This study tests a chemotherapy plan called N10 for children with high-risk neuroblastoma, a rare and aggressive cancer. The goal is to see if this reduced treatment is safe and can shrink tumors effectively. About 45 children under 19 with newly diagnosed high-risk neuroblastoma…

This study tests whether the drug hetrombopag can help children with neuroblastoma recover their platelets more quickly after a stem cell transplant. About 30 children will take the drug daily for up to 6 weeks. The main goal is to see if it reduces the need for platelet transfus…

This early-phase study tests a new combination treatment for children whose neuroblastoma or osteosarcoma has come back or not responded to standard therapy. It adds donated immune cells (gamma delta T cells) to a standard chemo and antibody regimen. The main goal is to find the …

This early-stage trial tests a targeted radiation therapy (PRRT) in 18 children whose neuroblastoma has returned or not responded to standard treatments. The therapy uses a radioactive drug that seeks out tumor cells. The main goal is to find the safest dose and watch for side ef…

This study is testing whether special PET scans using different radioactive tracers can accurately find and stage neuroblastoma and pheochromocytoma/paraganglioma tumors in people aged 6 months to 70 years. Participants will receive an injection of a tracer, then have a PET scan,…

This study tests a special fluorescent dye (anti-GD2-800CW) that makes neuroblastoma tumors glow during surgery. About 22 children aged 1 to 18 will receive the dye before their standard tumor removal surgery. The goal is to find a safe and effective dose so surgeons can better s…

This study looks at whether adding a special support program (called RISE) to usual care can reduce financial and material hardships for low-income families whose children are being treated for high-risk neuroblastoma. About 84 children and their parents will take part, with some…

This study watches how children and their caregivers recover after major cancer surgery. About 40 participants will wear smartwatches, answer surveys, and give extra blood samples before and up to a year after surgery. The goal is to find patterns in activity, sleep, and blood ma…

This study looks at whether a blood test can help doctors monitor neuroblastoma, a type of childhood cancer. Researchers will collect blood samples from 200 patients over time to check for tiny bits of tumor DNA. The goal is to see if these tests can show how well treatment is wo…

This study collects extra blood, urine, and tumor samples from children and adults with childhood cancers to create a large tissue bank. Researchers will use these samples to study the genes and proteins of these cancers. The goal is to better understand these diseases, not to te…

This study aims to understand the genetic and biochemical makeup of neuroblastic tumors, which can affect how aggressive the cancer is and what treatments work best. Researchers will analyze tumor samples, blood, bone marrow, and stem cells from over 2000 participants. The goal i…